SEC Foi	m 4 FORM	14	ι	JNITED	) STA	TES S	ECURITI	IES	S ANI	ΣE	ХСНА	NG	SE CO	OMM	ISSION				
Washington, D.C. 20549													OMB APPROVAL						
Section 16. Form 4 or Form 5 obligations may continue. See						ed pursuan	NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									Estim	Estimated average burden		3235-0287 :n 0.5
1. Name and Address of Reporting Person* <u>NIES ALAN S</u>						LEX	2. Issuer Name and Ticker or Trading Symbol <u>LEXICON PHARMACEUTICALS, INC.</u> [ LXRX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				
(Last) 2445 TE 11TH FI	CHNOL( LOOR		3. Date of Earliest Transaction (Month/Day/Year) 04/30/2022									)		below)					
(Street) THE TX 77381						4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(State)	(	Zip)															
			Tabl	e I - Nor	-Deriv	ative S	ecurities A	\cq	uired,	Disp	osed o	of, o	r Ben	eficial	ly Owne	d			
1. Title of Security (Instr. 3) Date (Month/E					action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount (A) (D)		(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(1150.4)
Common Stock 04/30						0/2022			М		4,02	4	A	\$ <mark>0</mark>	31	,744		D	
			Т				urities Ac Is, warrant		,			,			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of			Execution Date, T if any C		4. Transactio Code (Inst 8)		of Exp Derivative (Mo			ble and r)	Am Sec	itle and ount of urities lerlving		Derivative de Security Se		lumber of 10. ivative Owner surities Form: heficially Direct		11. Natur of Indirec Beneficia Ownersh

Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	SA: Deenled Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	\$0	04/30/2022		М			4,024	(1)	(2)	Common Stock	4,024	\$0	0	D	

Explanation of Responses:

1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

## <u>/s/ Alan S. Nies</u>

\*\* Signature of Reporting Person

05/02/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.